Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.
The extrinsic coagulation pathway is activated when circulating factor VII (FVII) gains access to tissue factor (TF) exposed as a consequence of vascular injury. Increasing evidence indicates that this TF-dependent activation of the coagulation plays an important role in the pathophysiology of intravascular thrombus formation. In the present study, we tested the effects of recombinant human, active site-blocked activated FVII (FVIIai) in a rabbit model of carotid artery thrombosis. Cyclic flow variations (CFVs), due to recurrent thrombus formation, were obtained in stenotic rabbit carotid arteries with endothelial injury. Carotid blood flow velocity was measured by a Doppler flow probe. After 30 minutes of CFVs, the animals received FVIIai (100 microg x kg(-1) x min(-1) intracarotid infusion for 10 minutes, n=9). If CFVs were abolished, animals were followed for 30 additional minutes, after which recombinant human activated FVII (FVIIa) was infused into the carotid artery (100 microg x kg(-1) x min(-1) for 10 minutes) to determine whether FVIIai could be displaced from TF by FVIIa, thus restoring CFVs. To establish the duration of action of FVIIai, an additional group of animals received FVIIai at the same dose as above, and after CFVs were inhibited, they were followed until CFVs were restored or for up to 6 hours. To determine whether CFVs could be restored by epinephrine after their abolition with FVIIai, increasing doses of epinephrine were administered to a third group of 6 animals. FVIIai abolished CFVs in 8 of 9 rabbits (P<.01). This effect was reversible, as FVIIa administration restored CFVs in all animals. Prothrombin times and activated partial thromboplastin times did not change significantly throughout the study. One single 10-minute infusion exerted complete antithrombotic effects for at least 6 hours, despite the fact that at this time point, plasma FVIIai levels were well below threshold concentrations. Epinephrine restored CFVs in 3 of 6 animals in which CFVs were inhibited by FVIIai. FVIIai exerts potent antithrombotic effects in this model; these effects were prolonged even after FVIIai was almost completely cleared from the circulation, probably as a result of the tight binding of FVIIai to TF. Thus, FVIIai might represent an antithrombotic substance of potential interest.
Golino
P
P
Department of Internal Medicine, 2nd School of Medicine, University of Naples, Italy. golino@ds.cised.unina.it
Ragni
M
M
Cirillo
P
P
D'Andrea
D
D
Scognamiglio
A
A
Ravera
A
A
Buono
C
C
Ezban
M
M
Corcione
N
N
Vigorito
F
F
Condorelli
M
M
Chiariello
M
M
D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D001783:Blood Flow Velocity / Q000187:drug effects; D002341:Carotid Artery Thrombosis / Q000188:drug therapy*; D004195:Disease Models, Animal; D004837:Epinephrine / Q000494:pharmacology; D015942:Factor VIIa / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014662:Vasoconstrictor Agents; D015942:Factor VIIa; D004837:Epinephrine